JPH04364856A - Rod for blocking lacrimal liquid - Google Patents
Rod for blocking lacrimal liquidInfo
- Publication number
- JPH04364856A JPH04364856A JP3138985A JP13898591A JPH04364856A JP H04364856 A JPH04364856 A JP H04364856A JP 3138985 A JP3138985 A JP 3138985A JP 13898591 A JP13898591 A JP 13898591A JP H04364856 A JPH04364856 A JP H04364856A
- Authority
- JP
- Japan
- Prior art keywords
- rod
- lacrimal
- copolymer
- weight
- damming
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000000903 blocking effect Effects 0.000 title abstract 2
- 239000007788 liquid Substances 0.000 title abstract 2
- 229920001577 copolymer Polymers 0.000 claims abstract description 14
- 239000000126 substance Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 abstract description 5
- YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 abstract description 4
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 abstract description 3
- 238000003780 insertion Methods 0.000 abstract description 3
- 230000037431 insertion Effects 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 238000001035 drying Methods 0.000 abstract 1
- 208000037921 secondary disease Diseases 0.000 abstract 1
- 239000012530 fluid Substances 0.000 description 7
- 241000083513 Punctum Species 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 3
- 206010013774 Dry eye Diseases 0.000 description 3
- 208000007654 attenuated familial adenomatous polyposis Diseases 0.000 description 2
- 239000002729 catgut Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- VBZWSGALLODQNC-UHFFFAOYSA-N hexafluoroacetone Chemical compound FC(F)(F)C(=O)C(F)(F)F VBZWSGALLODQNC-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- HVLLSGMXQDNUAL-UHFFFAOYSA-N triphenyl phosphite Chemical compound C=1C=CC=CC=1OP(OC=1C=CC=CC=1)OC1=CC=CC=C1 HVLLSGMXQDNUAL-UHFFFAOYSA-N 0.000 description 2
- VUBOQPNQIMKEKI-UHFFFAOYSA-N 3,8-dithiatricyclo[5.1.0.02,4]oct-5-en-4-ol Chemical compound C12SC2C=CC2(O)C1S2 VUBOQPNQIMKEKI-UHFFFAOYSA-N 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010984 Corneal abrasion Diseases 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- -1 collagen Natural products 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000004083 nasolacrimal duct Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000004489 tear production Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00772—Apparatus for restoration of tear ducts
Landscapes
- Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- Plastic & Reconstructive Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
【０００１】0001
【産業上の利用分野】本発明は、涙液せき止め用ロッド
に関する。更に詳しくは、溶解性の共重合体よりなる涙
液せき止め用ロッドに関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a tear damming rod. More specifically, the present invention relates to a tear damming rod made of a soluble copolymer.
【０００２】0002
【従来の技術】人間の日常生活において涙の役割は重要
である。目の乾燥を防ぎ、目に入ったゴミ等の異物を洗
い流すほか、殺菌作用も持っており、涙が減るとこれら
の働きが低下して角膜炎や結膜炎等の病気にかかりやす
くなることは周知の事実である。BACKGROUND OF THE INVENTION Tears play an important role in human daily life. In addition to preventing dryness of the eyes and washing away foreign substances such as dust that have entered the eyes, it also has a bactericidal effect, and it is well known that when tear production decreases, these functions decrease, making you more susceptible to diseases such as keratitis and conjunctivitis. This is a fact.
【０００３】また、近年の傾向として、テレビ画面を長
時間見つめるコンピューター作業従事者にドライアイ（
涙液減少症）患者が増えているとも言われている。涙腺
より分泌された涙液は角膜表面をぬらした後、鼻側に流
れ涙点に入り、涙小管、涙のう、鼻涙管を通って下鼻道
に流れ出る。この涙点から下鼻道に至るまでを涙道とい
う。Additionally, as a recent trend, computer workers who stare at television screens for long periods of time are experiencing dry eye (
It is also said that the number of patients with lachrymal hypolacrima is increasing. After wetting the corneal surface, the lacrimal fluid secreted by the lacrimal gland flows toward the nose, enters the lacrimal punctum, and flows out into the lower nasal passage through the lacrimal canaliculus, lacrimal sac, and nasolacrimal duct. The area from this lacrimal punctum to the inferior nasal meatus is called the lacrimal duct.
【０００４】上記した様なドライアイ患者に対して涙道
より流出する涙液量を減らす方法が提案されている。例
えば米国特許第３９４９７５０号明細書に記載されたよ
うな涙点プラグがある。この方法は涙道の入口に栓をし
て涙液の流出を止めようというものである。この方法に
よれば、プラグの上部が涙点から外に出ているためこの
部分が角膜にふれ、角膜に擦傷を起こすことがあるとと
もに、涙点より外れ易いといった欠点を有する。[0004] Methods have been proposed for reducing the amount of lachrymal fluid flowing out of the lacrimal duct for dry eye patients as described above. For example, there are punctal plugs, such as those described in US Pat. No. 3,949,750. This method involves placing a plug at the entrance of the tear duct to stop the flow of tear fluid. According to this method, since the upper part of the plug protrudes from the lacrimal punctum, this part comes into contact with the cornea, which may cause corneal abrasion, and it also has the disadvantage that it is easily removed from the lacrimal punctum.
【０００５】また特開昭６１−１１５５５９号公報には
、カットグットのロッドを、涙道に挿入することが提案
されている。カットグットすなわちコラーゲンは涙道に
挿入後、１０−１５日間で溶けてしまうので、プラスチ
ックロッドを挿入した時の様な長期滞留によるトラブル
の心配の無い方法であるが、コラーゲンは、その原料と
して天然の動物の腸などを使用するため、用いられる組
織の性質と自然の生物学的変化により、きめ、および溶
解速度のバラツキが大きいといった欠点がある。加えて
コラーゲンは抗源抗体反応が起こりやすく生体適合性に
問題があることは周知の事実である。[0005] Furthermore, Japanese Patent Laid-Open No. 61-115559 proposes inserting a catgut rod into the lacrimal duct. Catgut, or collagen, dissolves within 10-15 days after being inserted into the lacrimal duct, so there is no need to worry about problems caused by long-term retention like when inserting a plastic rod, but collagen is a natural raw material. Since the intestines of other animals are used, there are drawbacks such as large variations in texture and dissolution rate due to the properties of the tissue used and natural biological changes. In addition, it is a well-known fact that collagen is susceptible to antigen-antibody reactions and has biocompatibility problems.
【０００６】[0006]
【発明が解決しようとする課題】本発明は、上述のよう
な、使用時に発生する二次的な弊害が起こらない、均一
な溶解性を有る、溶解速度のバラツキが小さい涙液せき
止め用ロッドを提供することを目的とする。[Problems to be Solved by the Invention] The present invention provides a lachrymal fluid damming rod that does not cause the secondary adverse effects that occur during use as described above, has uniform solubility, and has small variations in dissolution rate. The purpose is to provide.
【０００７】[0007]
【課題を解決するための手段】本発明者等は、この様な
問題を解決するために各種材料について鋭意検討した結
果、下記化３で表わされる繰返し単位、[Means for Solving the Problems] As a result of intensive studies on various materials in order to solve such problems, the present inventors have developed a repeating unit represented by the following chemical formula 3,
【０００８】[0008]
【化３】[Chemical 3]
【０００９】および下記化４で表わされる繰返し単位、
and a repeating unit represented by the following formula 4,
【００１０】0010
【化４】[C4]
【００１１】から成る共重合体が、涙道内で溶解するこ
とを見出し本発明に至ったものである。上記式（Ｉ）で
表わされる繰返し単位および上記式（ＩＩ）で表わされ
る繰返し単位から成る共重合体は、縫合糸用の材料とし
て比較的よく知られた材料であり、生体組織内に於いて
溶解することは知られている。しかし必ずしも生体組織
内とはいいがたい涙道に於いて溶解するということは意
外な事実であった。The inventors have discovered that a copolymer consisting of the following is dissolved in the lacrimal duct, leading to the present invention. A copolymer consisting of a repeating unit represented by the above formula (I) and a repeating unit represented by the above formula (II) is a relatively well-known material for suture threads, and is a material that is relatively well-known as a material for suture threads. It is known to dissolve. However, it was a surprising fact that it dissolves in the lacrimal duct, which cannot necessarily be said to occur in living tissue.
【００１２】すなわち本発明は、９９〜１重量％の式（
Ｉ）で表わされる繰返し単位、および１〜９９重量％の
式（ＩＩ）で表わされる繰返し単位からなる共重合体よ
りなる涙液せき止め用ロッドである。涙液せき止め用ロ
ッドの使用は涙点より挿入することで行うが、その大き
さは通常、長さ０．５〜５ｍｍ、直径０．１〜１．５ｍ
ｍの範囲から選択され、長さ１．０〜３．０ｍｍ、直径
０．２〜０．８ｍｍが最も一般的である。しかしこれは
各個人の涙点の大きさ等により選択すべきものであり、
使用するに際して、ロッドの最適長さ、および半径を使
用する人に合わせて決定すればよい。That is, the present invention provides 99 to 1% by weight of the formula (
This is a lachrymal fluid damming rod made of a copolymer comprising repeating units represented by formula (I) and 1 to 99% by weight of repeating units represented by formula (II). A tear damming rod is inserted through the lacrimal punctum, and its size is usually 0.5 to 5 mm in length and 0.1 to 1.5 m in diameter.
m, with lengths of 1.0 to 3.0 mm and diameters of 0.2 to 0.8 mm being most common. However, this should be selected depending on the size of each individual's lacrimal puncta.
When using the rod, the optimum length and radius of the rod may be determined according to the user.
【００１３】本発明に用いる共重合体において、式（Ｉ
）で表わされる繰返し単位は、９９〜１重量％、好まし
くは９９〜５０重量％、より好ましくは９９〜６５重量
％であり、式（ＩＩ）で表わされる繰返し単位は１〜９
９重量％、好ましくは１〜５０重量％、より好ましくは
１〜３５重量％である。また、ヘキサフルオロアセトン
１．５水和物（ＨＦＡＳ）１００ｍｌ（３０℃）中０．
５ｇの共重合体溶液を使用して測定した固有粘度（Ｉ．
Ｖ．）が０．６〜１．２の共重合体であることが好まし
い。式（ＩＩ）で表わされる繰返し単位の比率が大きい
と涙液せき止め用ロッドとして使用した時の溶解時間が
必要以上に長くなり、長期滞留によるトラブルの原因に
なりかねない。また、上記固有粘度（Ｉ．Ｖ．）が０．
６未満では溶融成形が難しく、逆に１．２を越えると溶
融粘度が大きくなり、これまた溶融成形が難しくなる。In the copolymer used in the present invention, the formula (I
) The repeating unit represented by formula (II) is 99 to 1% by weight, preferably 99 to 50% by weight, more preferably 99 to 65% by weight, and the repeating unit represented by formula (II) is 1 to 9% by weight.
9% by weight, preferably 1-50% by weight, more preferably 1-35% by weight. In addition, 0.0% in 100 ml (30°C) of hexafluoroacetone hemihydrate (HFAS).
Intrinsic viscosity (I.
V. ) is preferably 0.6 to 1.2. If the ratio of the repeating unit represented by formula (II) is large, the dissolution time when used as a tear damming rod becomes longer than necessary, which may cause troubles due to long-term retention. Further, the above-mentioned intrinsic viscosity (I.V.) is 0.
If it is less than 6, melt molding will be difficult, and if it exceeds 1.2, the melt viscosity will increase, which will also make melt molding difficult.
【００１４】本発明に用いる共重合体は、例えば特公昭
６３−４７７３１号公報に示されるように、トリメチレ
ンカーボネート及びグリコリドを単量体として製造する
ことが出来る。このようにして得られた共重合体を、プ
ランジャー押出機等を用い溶融紡糸し冷却固化した後こ
れを所望の長さにカットすることにより、涙液せき止め
用ロッドを得ることができる。The copolymer used in the present invention can be produced using trimethylene carbonate and glycolide as monomers, for example, as shown in Japanese Patent Publication No. 63-47731. The thus obtained copolymer is melt-spun using a plunger extruder or the like, cooled and solidified, and then cut into a desired length to obtain a lachrymal fluid damming rod.
【００１５】この様にして得られた涙液せき止め用ロッ
ドは、コラーゲンのような天然物を素材としないことか
ら、自然界の生物学的影響により発生する不利益、例え
ば溶解性の不均一性等は大巾に改善されている。上記共
重合体を安定化させる目的で、例えば、末端基をエステ
ル化したような化合物によってなる涙液せき止め用ロッ
ドも本発明に含まれることは言うまでもない。[0015] Since the tear damming rod thus obtained is not made of natural products such as collagen, it is free from disadvantages caused by biological influences in nature, such as non-uniform solubility. has been greatly improved. Needless to say, the present invention also includes a lacrimal fluid damming rod made of a compound in which the terminal group is esterified for the purpose of stabilizing the copolymer.
【００１６】また、挿入時の取扱い性を改良する目的で
、各種界面活性剤、例えばステアリン酸カルシウムの様
なコーティング剤によってコートして用いることも可能
である。また、トリフェニルホスファイト、ジアルキル
フェノールスルファイド、二硫化芳香族フェノールに例
示されるような安定剤を添加することも可能である。[0016] Furthermore, for the purpose of improving handling properties during insertion, it is also possible to use a coating with various surfactants, such as a coating agent such as calcium stearate. It is also possible to add stabilizers such as triphenyl phosphite, dialkylphenol sulfide, and aromatic phenol disulfide.
【００１７】また所望により適当な着色剤により着色す
ることも可能である。[0017] It is also possible to color with a suitable coloring agent if desired.
【００１８】[0018]
【実施例】次に実施例により本発明をさらに詳細に説明
する。EXAMPLES Next, the present invention will be explained in more detail with reference to Examples.
【００１９】[0019]
【実施例１】特公昭６３−４７７９１号公報に記載の方
法で、ヘキサフルオロアセトン１．５水和物（ＨＦＡＳ
）１００ｍｌ（３０℃）中０．５ｇの共重合体溶液を使
用して測定した固有粘度０．８０、共重合体中のトリメ
チレンカーボネート単位１５重量％（１７モル％相当）
のトリメチレンカーボネートとグリコリドからなる共重
合体を得た。この共重合体を、プランジャー押出機に挿
入し２３０℃で溶融紡糸し、水中にて冷却固化したもの
をカッターにより切り、径０．３ｍｍφ、長さ２ｍｍの
涙液せき止め用ロッドを得た。[Example 1] Using the method described in Japanese Patent Publication No. 63-47791, hexafluoroacetone hemihydrate (HFAS)
) Intrinsic viscosity 0.80 measured using 0.5 g of copolymer solution in 100 ml (30°C), 15% by weight (equivalent to 17 mol%) of trimethylene carbonate units in the copolymer
A copolymer of trimethylene carbonate and glycolide was obtained. This copolymer was inserted into a plunger extruder and melt-spun at 230°C, cooled and solidified in water, and cut with a cutter to obtain a tear damming rod with a diameter of 0.3 mmφ and a length of 2 mm.
【００２０】このロッドを１ｍｍ長のロッドにしたもの
を、体重３．５ｋｇおよび３．４ｋｇの二羽の白色ウサ
ギの左右の涙点より挿入した。３ケ月後涙道を切開した
ところ、ロッドは溶解消失していた。[0020] This rod with a length of 1 mm was inserted into the left and right lacrimal puncta of two white rabbits weighing 3.5 kg and 3.4 kg. Three months later, when the lachrymal duct was incised, the rod had dissolved and disappeared.
【００２１】[0021]
【発明の効果】本発明の涙液せき止め用ロッドを用いる
ことにより、ドライアイ症状が軽減され、溶解速度が均
一であることから挿入スケジュール管理が容易であり、
加えて生体適合性に関する不安も軽減される。[Effects of the Invention] By using the tear damming rod of the present invention, dry eye symptoms are alleviated, and the dissolution rate is uniform, making it easy to manage the insertion schedule.
In addition, concerns regarding biocompatibility are also alleviated.
Claims (1)
る繰返し単位、 【化１】 および１〜９９重量％の下記化２で表わされる繰返し単
位 【化２】 から成る共重合体よりなる涙液せき止め用ロッド。[Claim 1] Consisting of a copolymer consisting of 99 to 1% by weight of a repeating unit represented by the following formula 1, [Chemical 1] and 1 to 99% by weight of a repeating unit represented by the following formula 2 [Chemical 2] Rod for lachrymal drainage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3138985A JPH04364856A (en) | 1991-06-11 | 1991-06-11 | Rod for blocking lacrimal liquid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3138985A JPH04364856A (en) | 1991-06-11 | 1991-06-11 | Rod for blocking lacrimal liquid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH04364856A true JPH04364856A (en) | 1992-12-17 |
Family
ID=15234788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3138985A Withdrawn JPH04364856A (en) | 1991-06-11 | 1991-06-11 | Rod for blocking lacrimal liquid |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH04364856A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0693277A1 (en) | 1994-06-24 | 1996-01-24 | Koken Co. Ltd. | Method for obstructing lacrimal canaliculi with infusible solution or dispersion |
-
1991
- 1991-06-11 JP JP3138985A patent/JPH04364856A/en not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0693277A1 (en) | 1994-06-24 | 1996-01-24 | Koken Co. Ltd. | Method for obstructing lacrimal canaliculi with infusible solution or dispersion |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Phelps et al. | Open-angle glaucoma following surgery for congenital cataracts | |
| Watson et al. | The complications of trabeculectomy (a 20-year follow-up) | |
| Maumenee | The pathogenesis of congenital glaucoma: a new theory | |
| Glasser et al. | A comparison of the efficacy and toxicity of and intraocular pressure response to viscous solutions in the anterior chamber | |
| JP3486758B2 (en) | Injectable lacrimal canaliculus | |
| Baxter et al. | Punctal plugs in the management of dry eyes | |
| EA000790B1 (en) | Composition for use in ophthalmologic surgery and method therefor | |
| JP2009540951A (en) | Puncture plug for active agent delivery | |
| DUNNINGTON et al. | Incorporation of S35 in healing wounds in normal and devitalized corneas | |
| CN101505696B (en) | Punctal plugs for the delivery of active agents | |
| Kooner et al. | Intraocular pressure following ECCE, phacoemulsification, and PC-IOL implantation | |
| Bleiman et al. | Paradoxical intraocular pressure response to pilocarpine: a proposed mechanism and treatment | |
| Bischoff et al. | High blood pressure in choroidal arteries as a possible pathogenetic mechanism in senile macular degeneration | |
| Alpar | Sodium hyaluronate (Healon®) in glaucoma filtering procedures | |
| JPH04364856A (en) | Rod for blocking lacrimal liquid | |
| Lazenby et al. | The use of sodium hyaluronate (Healon) in intracapsular cataract extraction with insertion of anterior chamber intraocular lenses | |
| Fry et al. | Healon GV in extracapsular cataract extraction with intraocular lens implantation | |
| JPH04364857A (en) | Rod for blocking lacrimal duct | |
| JPH04364839A (en) | Rod for closing lacrimal duct | |
| Maguire et al. | Migration of solid silicone encircling element through four rectus muscles | |
| JPH04364842A (en) | Rod for insertion into lacrimal duct | |
| Peduzzi et al. | Abnormal blood viscosity and erythrocyte deformability in retinal vein occlusion | |
| Ophir et al. | Encapsulated filtering bleb and subconjunctival 5-fluorouracil | |
| Al Samarrai et al. | Incidence of posttrabeculectomy cataract among Arabs in Kuwait | |
| JPH0592015A (en) | Rod for preventing outflow of tears |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A300 | Application deemed to be withdrawn because no request for examination was validly filed |
Free format text: JAPANESE INTERMEDIATE CODE: A300 Effective date: 19980903 |